about
Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight GainRandomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset SchizophreniaA Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode SchizophreniaSchizophrenia TreAtment With electRic Transcranial StimulationCurcumin as a Novel Treatment to Improve Cognitive Dysfunction in SchizophreniaCromoglycate Adjunctive Therapy for Outpatients With SchizophreniaOndansetron for Bipolar Disorder and Alcohol Use DisordersPilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course SchizophreniaA Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase SchizophreniaFamotidine in SchizophreniaStudy of Immunotherapy in Autoantibody Positive PsychosisExenatide Weekly Injections as an Adjunctive Treatment in Patients With SchizophreniaTocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaTargeted Vitamin D Treatment of Schizophrenia-Associated HyperprolinemiaMinocycline for SchizophreniaKuvan in People With Schizophrenia and Schizoaffective DisorderSupraphysiological Doses of Levothyroxine as Adjunctive Therapy in Bipolar DepressionMinocycline and Aspirin in the Treatment of Bipolar DepressionArtemisinin With Risperidone for First-Episode and Drug-Naive SchizophreniaMelatonin Treatment for Tardive Dyskinesia in SchizophreniaEffects of Pravastatin on Cholesterol, Inflammation and Cognition in SchizophreniaAn Exploratory Open Label Study of Adjunctive L-lysine Treatment in Patients With SchizophreniaMagnetic Seizure Therapy (MST) for the Treatment of Major DepressionCytidine and Omega-3 Fatty Acids in Bipolar DisorderEfficacy of Adjunctive Tianeptine in the Treatment of Bipolar DepressionA Trial of SAMe for Treatment-Resistant Bipolar DepressionArtemisinin to Reduce The Symptoms of SchizophreniaThe Use of a Mitochondrial Enhancement Treatment in Bipolar DisorderSafety Study of ACP-104: To Demonstrate the Safety, Tolerability, and PharmacokineticsTreating Cognition in Schizophrenia With Atomoxetine and Cognitive RemediationZiprasidone in Pediatric Bipolar DisorderEfficacy of Pregnenolone in Patients With SchizophreniaCognitive Enhancement in Bipolar DisorderAdd-on Simvastatin in Schizophrenia TrialCannabidiol Treatment of Cognitive Dysfunction in SchizophreniaLow Field Magnetic Stimulation in Mood Disorders Using the LFMS DeviceEstradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform DisorderTreating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar DisorderControlled Trial of Valproate Versus Risperidone in Young Children With Bipolar DisorderDietary Intervention for Bipolar Disorder
P767
Q64041192-16C8FC06-2A32-4177-A90D-A29DC88D5F77Q64044017-C85904A1-41ED-45DD-8DBE-FD0EC0FAB423Q64045764-35CD3EAF-F816-4E11-A02E-BC6DC66A5B49Q64139562-60C2CAAC-54BA-49AE-9173-DFC0FBE6800EQ64140224-0BFE8E23-6848-4492-9227-AD01411D5F3CQ64183759-EEBA565E-40C6-498D-B7A1-2BAC1451C0C2Q64221682-D3653E19-6012-4AF8-A0B2-282363B2152AQ64351047-28D9F464-539F-4DFB-B035-1AD00A180DBAQ64351285-994CCEB4-3CDF-4326-9339-BE9AD358BDF3Q64354426-E08FE332-65B7-4F2B-BA6D-E5DBE51A29C6Q64375605-9ADDF497-B481-43F7-97AD-7580DC0383D3Q64396086-14BF411C-4348-4002-A9DA-AFE74640B4D8Q64397665-B029CF41-8DD0-4531-8AD0-AB42CE6E4476Q64610083-EDE60F8C-C91C-426E-86CE-BF793688AA1DQ64626371-86B3D62E-9829-4F5F-9EC7-58E6DA1D100CQ64639408-64C212C0-65A3-4545-ADF3-E702A1E8082DQ64646993-48A89ACC-03CD-40B8-9615-BCF52FCC600DQ64648441-F1837556-11EE-41F7-AF27-E11317DF6B51Q64650123-0478DAD2-335D-44FA-A65C-F24722D0688BQ64650125-96F97C14-06F0-4174-82B6-BE9A5D62CDF8Q64655857-19C45D04-568A-4ED3-9699-921CC4086443Q64661881-16680377-DA69-4A2E-801C-AF8CC357B68FQ64663479-3EBF0A91-075E-4F48-8CEB-63E0F2594CF9Q64679553-F8FBB5C9-7252-405B-BD2E-D890CB4CCA09Q64680008-35B8F93C-62ED-46AA-A41B-6888393EAC66Q64714696-F58B313F-9771-4285-9462-DE366CEFDD3BQ64716256-3A1EBDFD-AD76-4918-A786-051673380DD6Q64717847-79AF1050-B153-464C-9B28-1F055F1C4C90Q64721734-C33DA695-15CD-4496-8B78-D799ABD8A8E4Q64721814-BB9F8312-0180-4D5A-950E-784003B0868AQ64722561-9304F550-266F-4B92-8709-81DE9C41F652Q64723522-5F5AEE49-80B4-4679-94A9-BF7771CF3D0FQ64724188-4C1280BD-FBB1-4AEC-96FF-733AE7E07175Q64725099-552B94EE-D92D-4667-AD9B-88D55C2769ADQ64725629-9C8EEABF-9B30-4AE7-B6A6-7A408694CB48Q64727103-63834F8A-B16F-4599-A8E4-83A377CB717BQ64793994-7E43D84C-7BFF-4916-9778-C83B5767946DQ65340184-52461251-1712-426B-8EE3-A586B39996C5Q65347598-9C13FA0F-DC12-4353-8D2F-8E31CE1F0081Q65351754-F9AFA491-8ED1-47C5-881E-576B3E74650C
P767
description
amerikanische Non-Profit-Organisation
@de
nonprofit organization in Chevy Chase, United States
@en
name
Stanley Medical Research Institute
@en
type
label
Stanley Medical Research Institute
@en
altLabel
SMRI
@en
prefLabel
Stanley Medical Research Institute
@en
P3153
P131
P213
0000 0004 0473 2858
P2427
grid.453353.7
P3153
P3500
P571
1989-01-01T00:00:00Z
P625
Point (-77.076353 38.994345)